Rasilez and Levemir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Rasilez and Levemir. Common interactions include hyperkalaemia among females and acute myocardial infarction among males.

The phase IV clinical study analyzes what interactions people who take Rasilez and Levemir have. It is created by eHealthMe based on reports of 31 people who take Rasilez and Levemir from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 02, 2023

31 people who take Rasilez and Levemir together, and have interactions are studied.

What is Rasilez?

Rasilez has active ingredients of aliskiren hemifumarate. It is often used in high blood pressure. eHealthMe is studying from 5,935 Rasilez users for its effectiveness, alternative drugs and more.

What is Levemir?

Levemir has active ingredients of insulin detemir recombinant. It is often used in diabetes. eHealthMe is studying from 13,828 Levemir users for its effectiveness, alternative drugs and more.

Number of Rasilez and Levemir reports submitted per year:

Common Rasilez and Levemir drug interactions by gender *:

female:

Hyperkalaemia
Blood calcium increased
Blood creatinine increased
Blood urea increased
Venous thrombosis
Renal impairment
Creatinine renal clearance decreased
Blood cholesterol increased
Lactic acidosis
Long qt syndrome

male:

Acute myocardial infarction
Blood pressure decreased
Diabetic foot
Hypertensive crisis
Hypocalcaemia
Hypoglycaemic unconsciousness
Loss of consciousness
Blood glucose increased
Cardiac failure
Glaucoma

Common Rasilez and Levemir drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Corneal dystrophy
Creatinine renal clearance decreased
Dry eye
Eye pain
Renal impairment

50-59:

Renal impairment
Arthralgia
Blood creatine increased
Creatinine renal clearance decreased
Exostosis
Fall
Hyperkalaemia
Lactic acidosis
Long qt syndrome
Metabolic acidosis

60+:

Blood creatinine increased
Hyperkalaemia
Blood cholesterol increased
Urinary tract infection
Aortic arteriosclerosis
Bundle branch block left
Coronary artery disease
Diabetic foot
Hypertensive crisis
Hypocalcaemia

Common conditions people have *:

Coronary Heart Disease (narrowing or blockage of the coronary arteries): 7 people, 22.58%
Pneumonia: 4 people, 12.90%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 4 people, 12.90%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 4 people, 12.90%
Cardiac Failure: 4 people, 12.90%
Cardiomyopathy (weakening of the heart muscle): 3 people, 9.68%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Rasilez and Levemir?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.